Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Sep 20;13(9):e0204364.
doi: 10.1371/journal.pone.0204364. eCollection 2018.

Sentinel lymph node biopsy mapped with methylene blue dye alone in patients with breast cancer: A systematic review and meta-analysis

Jiyu Li  1 , Xiao Chen  1 , Ming Qi  1 , Yanshuang Li  2
Affiliations
Meta-Analysis

Sentinel lymph node biopsy mapped with methylene blue dye alone in patients with breast cancer: A systematic review and meta-analysis

Jiyu Li et al. PLoS One. .

Abstract

Background: Methylene blue dye is easy to obtain in developing countries and can be used in sentinel lymph node mapping for breast cancer. However, the accuracy of methylene blue alone for sentinel lymph node mapping in breast cancer has not been well defined. In this study, we collected data to assess the feasibility and accuracy of sentinel lymph node biopsy mapped with methylene blue alone in patients with breast cancer.

Methods: We searched the PubMed, EMBASE, and Cochrane Library databases from January 1, 1993, to March 31, 2018. Selected studies had to have a defined group of patients with breast cancer in which MBD alone was used as the mapping technique for SNB.

Results: 18 studies were included in this study. The combined identification rate was 91% [95% confidence interval (CI): 88%-94%, I2 = 68.3%], and the false negative rate was 13% (95% CI: 9%-18%, I2 = 36.7%). The pooled sensitivity, negative predictive value, and accuracy rate were 87% (95% CI: 82%-91%, I2 = 37.5%), 91% (95% CI: 87%-93%, I2 = 32.4%) and 94% (95% CI: 92%-96%, I2 = 29%), respectively.

Conclusions: This meta-analysis found that mapping sentinel lymph node locations with methylene blue dye alone results in an acceptable identification rate but an excessive false negative rate according to the American Society of Breast Surgeons' recommendations. Caution is warranted when using methylene blue dye alone as the mapping method for sentinel lymph node biopsy.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Flow diagram of the literature search and individual studies identified for this systematic review and meta-analysis.
Fig 2
Fig 2. The combined IR and FNR of SNBs mapped with MBD alone.
A: A random-effects model was used to estimate the combined IR, with a result of 91% (95% CI: 88%-94%, I2 = 68.3%); B: A fixed-effects model was used to estimate the pooled FNR, with a result of 13% (95% CI: 9%-18%, I2 = 36.7%).
Fig 3
Fig 3. The combined sensitivity, NPV, and AR of SNBs mapped with MBD alone.
A: The pooled sensitivity was 87% (95% CI: 82%-91%, I2 = 37.5%); B: The combined NPV was 91% (95% CI: 87%-93%, I2 = 32.4%); C: The overall AR was 94% (95% CI: 92%-96%, I2 = 29%).
Fig 4
Fig 4. The combined IR for studies using peritumoral injection and studies using subareolar injection.
A: The combined IR for studies using peritumoral injection was 89% (95% CI: 83%-93%, I2 = 62.3%); B: The combined IR for studies using subareolar injection was 94% (95% CI: 89%-97%, I2 = 60.3%).
Fig 5
Fig 5. The combined FNR for studies using peritumoral injection and studies using subareolar injection.
A: The combined FNR for studies using peritumoral injection was 11% (95% CI: 7%-18%, I2 = 35.9%); B: The combined FNR for studies using subareolar injection was 6% (95% CI: 2%-17%, I2 = 0%).
Fig 6
Fig 6. The combined IR of SNB according to different MBD dose.
A: The combined IR for the studies that used a 2-ml injection of MBD was 90% (95% CI: 77%-96%, I2 = 70.3%); B: The combined IR for the studies that used a 5-ml injection of MBD was 92% (95% CI: 87%-95%, I2 = 67.1%).
Fig 7
Fig 7. The combined FNR of SNB according to different MBD dose.
A: The combined FNR for the studies that used a 2-ml injection of MBD was 11% (95% CI: 5%-22%, I2 = 0%); B: The combined FNR for the studies that used a 5-ml injection of MBD was 10% (95% CI: 6%-16%, I2 = 0%).
Fig 8
Fig 8. Funnel plots used to assess the effects of publication bias on the IR and FNR.
A: Funnel plot to assess publication bias effect on the IR; B: Funnel plot to assess publication bias on the FNR. Each dot represents a separate study. The funnel plots revealed no apparent evidence of publication bias.
See this image and copyright information in PMC

References

    1. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127(4):392–9. . - PubMed
    1. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220(3):391–8; discussion 8–401. . - PMC - PubMed
    1. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927–33. 10.1016/S1470-2045(10)70207-2 . - DOI - PMC - PubMed
    1. Lyman GH, Temin S, Edge SB, Newman LA, Turner RR, Weaver DL, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014;32(13):1365–83. 10.1200/JCO.2013.54.1177 . - DOI - PubMed
    1. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349(6):546–53. 10.1056/NEJMoa012782 . - DOI - PubMed

MeSH terms